Synopsis: PI Industries Ltd is in focus after Jefferies initiated coverage with a “Buy” rating and a target price of ₹3,575. Despite weak agrochemical demand, export pressure, and margin challenges, the brokerage expects FY27 recovery driven by new molecule launches, improving product mix, stronger pharma CDMO growth, and gradual demand normalization.
The shares of a Mid-cap company specializing in complex chemistry, particularly in custom synthesis and contract research and manufacturing services (CSM) for global life sciences companies, are in focus after Jefferies initiated coverage with a “Buy” rating. In this article, also see whether new molecule launches can offset weakness in the agrochemical segment.
With a market capitalization of Rs. 42,223.15 crores in the day’s trade, the shares of PI Industries Ltd rose by 3 percent, reaching a high of Rs. 2,820.10 per share compared to its previous closing price of Rs. 2,736.30 per share.
What Happened
PI Industries Ltd, engaged in complex chemistry, particularly in custom synthesis and contract research and manufacturing services (CSM) for global life sciences companies are in focus after Jefferies initiated coverage with a “Buy” rating with a target price of Rs. 3575 with an upside potential of 31 percent from the previous day’s close.
Reason for the target
Rise in working capital
The company saw a sharp increase in working capital requirements, which impacted cash flows and operational efficiency. Higher inventory and receivables levels added pressure on the balance sheet, making analysts cautious about near-term execution and margin sustainability.
FY27 recovery expectations
Management expects growth to improve in FY27, supported by a favorable base effect and contribution from new molecules. Analysts believe recovery in exports, improving product mix, and gradual demand normalization could help the company achieve high-single-digit revenue growth over the next few years.
Long-term earnings outlook remains positive
Despite short-term challenges, analysts forecast adjusted PAT CAGR of nearly 12% over FY26–FY28E. Strong order inflows, expansion into new chemistries, and scaling up of pharma CDMO operations are expected to support long-term earnings growth and margin improvement.
Q4 earnings performance
PI Industries reported lower-than-expected EBITDA and PAT due to weaker demand in the agrochemical segment and margin pressure. Lower exports and softer domestic agri revenues impacted profitability, leading brokerages to remain cautious despite expectations of a gradual recovery in the coming years.
Key products
Growth in new products has moderated, while pyroxasulfone, one of the company’s major molecules, witnessed a sharp contraction amid rising competition and weak global demand. This affected overall revenue momentum and raised concerns about near-term growth visibility in the core agrochemical business.
Financials
The company’s revenue declined by 12.42 percent from Rs. 1,787 crores in March 2025 to Rs. 1,565 crores in March 2026. Meanwhile, Net profit declined from Rs. 330 crores to Rs. 200 crores in the same period.
The company maintains healthy financial fundamentals with an ROCE of 14.7% and ROE of 11.6%, indicating efficient capital utilization and stable profitability. It also has a very low debt-to-equity ratio of 0.03, reflecting a strong balance sheet and minimal reliance on debt funding.
The company reported a ~15% decline in agrochemical exports due to the ongoing contraction in the global agrochemical industry. Domestic revenue also softened by around 9% YoY despite volume growth of nearly 3%, impacted by elevated market inventory levels, pricing pressure, and lower acreage for key crops. The biologicals segment remained largely flat in Q4FY26 amid regulatory normalization.
Pharma revenue showed better performance, with Phormo1 revenue rising 23% YoY, while the pharma segment contributed around 8% of export revenue. Improved product mix and cost discipline supported gross margin expansion, although overhead costs increased due to investments in new businesses and product promotions.
The effective tax rate (ETR) increased to around 22% in FY26 due to a higher share of non-SEZ business during Q4FY26. Meanwhile, the board approved a final dividend of ₹10 per share for FY25-26, taking the total dividend for the year to ₹15 per share, including the interim dividend.
PI Industries Ltd is a leading Indian agrochemical and specialty chemicals company focused on complex chemistry solutions. The company operates across agri-sciences, custom synthesis, and contract research and manufacturing services (CRDMO) for global life sciences and pharmaceutical companies. It has built strong partnerships with several multinational innovators through its export-oriented business model.
The company has a strong global presence with operations across 40+ countries, supported by 10 overseas offices and 8 manufacturing sites. It also has an extensive distribution network comprising 25 stock points, over 100,000 retail points, and a workforce of more than 4,000 employees.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post PI Industries: Can New Molecules Drive Growth Despite Agrochemical Weakness? appeared first on Trade Brains.